Drug intelligence / Profile preview

propofol + rocuronium + sevoflurane + nitrous oxide

Development stage
Unknown
Lead developer
AkzoNobel
Modality
Small Molecules
Administration
Intravenous, Inhalation
01

Overview

This is a combination of four agents commonly used in general anesthesia: - **Propofol** is an intravenous anesthetic agent used for induction and maintenance of general anesthesia. It acts primarily as a positive allosteric modulator at the gamma-aminobutyric acid type A (GABA-A) receptor, enhancing inhibitory neurotransmission in the central nervous system[1][3]. - **Rocuronium** is a non-depolarizing neuromuscular blocking agent (muscle relaxant) that competitively inhibits acetylcholine at nicotinic receptors on the motor endplate, resulting in skeletal muscle paralysis. It facilitates tracheal intubation and provides muscle relaxation during surgery[4][5]. - **Sevoflurane** is an inhalational volatile anesthetic used for induction and maintenance of general anesthesia. It enhances GABAergic inhibition via GABA-A receptors and also affects other ion channels to produce its effects[4]. - **Nitrous oxide (N2O)** is an inhaled anesthetic gas with analgesic properties. It acts as an NMDA receptor antagonist among other mechanisms but cannot provide full surgical anesthesia alone; it is typically combined with more potent agents like sevoflurane[2][4]. This combination provides rapid induction of unconsciousness (propofol), muscle relaxation for intubation/surgery (rocuronium), maintenance of anesthesia with rapid emergence profile (sevoflurane), and additional analgesia/anesthetic depth modulation (nitrous oxide). This regimen allows titration to patient needs during surgery.

Other names
propofol + rocuronium + sevoflurane + N2Opropofol, rocuronium, sevoflurane, and nitrous oxide combination
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)Muscle-type nicotinic acetylcholine receptor

Beyond the preview

Go deeper on propofol + rocuronium + sevoflurane + nitrous oxide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on propofol + rocuronium + sevoflurane + nitrous oxide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call